Novartis To Ape Aimovig's US Market Strategy In The EU As CHMP Gives Market Go-Ahead

 
• By Alexandra Shimmings

Swiftly following its first approval in the US, Amgen/Novartis' Aimovig has just been given a CHMP go-ahead in the EU positioning it to be the first CGRP targeting agent on the market there. Launch tactics look set to mirror those in the US.

Human brain illustrated with millions of small nerves - Conceptual 3d render

More from New Products

More from Scrip